Bioneer Corporation (064550.KQ)
KRW 19520.0
(-3.84%)
KRW 19520.0
(-3.84%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -3.9 Billion KRW | 75.54% |
| 2022 | -15.97 Billion KRW | 43.69% |
| 2021 | -28.37 Billion KRW | -48.32% |
| 2020 | -19.12 Billion KRW | -185.88% |
| 2019 | 22.27 Billion KRW | 54.39% |
| 2018 | 14.42 Billion KRW | -0.64% |
| 2017 | 14.52 Billion KRW | -30.65% |
| 2016 | 20.93 Billion KRW | 19.77% |
| 2015 | 17.48 Billion KRW | -27.15% |
| 2014 | 23.99 Billion KRW | -12.86% |
| 2013 | 27.53 Billion KRW | 1703.99% |
| 2012 | -1.71 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -7.29 Billion KRW | -553.6% |
| 2024 Q1 | -1.11 Billion KRW | 71.43% |
| 2023 Q3 | -11.41 Billion KRW | -18.89% |
| 2023 Q4 | -3.9 Billion KRW | 65.77% |
| 2023 Q1 | -14.84 Billion KRW | 7.1% |
| 2023 FY | -3.9 Billion KRW | 75.54% |
| 2023 Q2 | -9.6 Billion KRW | 35.31% |
| 2022 Q3 | 1.6 Billion KRW | -51.17% |
| 2022 FY | -15.97 Billion KRW | 43.69% |
| 2022 Q4 | -15.97 Billion KRW | -1095.5% |
| 2022 Q2 | 3.28 Billion KRW | 122.46% |
| 2022 Q1 | -14.63 Billion KRW | 48.43% |
| 2021 Q1 | -12.05 Billion KRW | 39.44% |
| 2021 Q4 | -28.37 Billion KRW | -102.12% |
| 2021 FY | -28.37 Billion KRW | -48.32% |
| 2021 Q3 | -14.03 Billion KRW | -52.11% |
| 2021 Q2 | -9.22 Billion KRW | 23.44% |
| 2020 FY | -19.12 Billion KRW | -185.88% |
| 2020 Q2 | 6.91 Billion KRW | -68.0% |
| 2020 Q3 | -14.6 Billion KRW | -311.1% |
| 2020 Q4 | -19.9 Billion KRW | -36.31% |
| 2020 Q1 | 21.61 Billion KRW | -1.63% |
| 2019 Q1 | 12.17 Billion KRW | -15.59% |
| 2019 Q2 | 12.77 Billion KRW | 4.92% |
| 2019 Q3 | 12.27 Billion KRW | -3.9% |
| 2019 FY | 22.27 Billion KRW | 54.39% |
| 2019 Q4 | 21.97 Billion KRW | 78.93% |
| 2018 Q1 | 14.67 Billion KRW | 1.03% |
| 2018 FY | 14.42 Billion KRW | -0.64% |
| 2018 Q4 | 14.42 Billion KRW | -50.72% |
| 2018 Q3 | 29.27 Billion KRW | 0.16% |
| 2018 Q2 | 29.23 Billion KRW | 99.25% |
| 2017 FY | 14.52 Billion KRW | -30.65% |
| 2017 Q4 | 14.52 Billion KRW | 14.11% |
| 2017 Q3 | 12.72 Billion KRW | 157.64% |
| 2017 Q2 | 4.93 Billion KRW | -76.44% |
| 2017 Q1 | 20.96 Billion KRW | -4.65% |
| 2016 Q2 | 20.48 Billion KRW | 1.11% |
| 2016 FY | 20.93 Billion KRW | 19.77% |
| 2016 Q3 | 23.16 Billion KRW | 13.07% |
| 2016 Q4 | 21.99 Billion KRW | -5.06% |
| 2016 Q1 | 20.25 Billion KRW | 15.79% |
| 2015 Q1 | 25.66 Billion KRW | 6.95% |
| 2015 Q4 | 17.49 Billion KRW | 2.44% |
| 2015 Q3 | 17.07 Billion KRW | -34.69% |
| 2015 Q2 | 26.14 Billion KRW | 1.89% |
| 2015 FY | 17.48 Billion KRW | -27.15% |
| 2014 Q2 | 23.16 Billion KRW | -12.37% |
| 2014 Q3 | 25.75 Billion KRW | 11.2% |
| 2014 Q4 | 23.99 Billion KRW | -6.83% |
| 2014 Q1 | 26.42 Billion KRW | -4.02% |
| 2014 FY | 23.99 Billion KRW | -12.86% |
| 2013 FY | 27.53 Billion KRW | 1703.99% |
| 2013 Q4 | 27.53 Billion KRW | 2.57% |
| 2013 Q3 | 26.84 Billion KRW | 2.53% |
| 2013 Q2 | 26.18 Billion KRW | -4.37% |
| 2013 Q1 | 27.38 Billion KRW | 1694.93% |
| 2012 FY | -1.71 Billion KRW | 0.0% |
| 2012 Q4 | -1.71 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Co., Ltd. | -46.18 Billion KRW | 91.539% |
| iNtRON Biotechnology, Inc. | -40.58 Billion KRW | 90.371% |
| BINEX Co., Ltd. | 45.34 Billion KRW | 108.617% |
| Anterogen.Co.,Ltd. | 8.35 Billion KRW | 146.79% |
| MEDIPOST Co., Ltd. | 14.81 Billion KRW | 126.378% |
| CrystalGenomics, Inc. | 8.99 Billion USD | 143.459% |
| Helixmith Co., Ltd | -24.42 Billion KRW | 84.001% |
| Chabiotech Co.,Ltd. | 388.94 Billion KRW | 101.005% |
| Medy-Tox Inc. | 49.58 Billion KRW | 107.881% |
| Peptron, Inc. | 4.86 Billion KRW | 180.265% |
| Amicogen, Inc. | 125.26 Billion KRW | 103.12% |
| Genexine, Inc. | 61.39 Billion KRW | 106.365% |
| HLB Therapeutics Co.,Ltd. | -13.68 Billion KRW | 71.448% |
| LegoChem Biosciences, Inc. | -56.05 Billion KRW | 93.028% |
| ALTEOGEN Inc. | 53.56 Billion KRW | 107.295% |
| PharmaResearch Co., Ltd. | -32.93 Billion KRW | 88.136% |
| SillaJen, Inc. | -13.89 Billion KRW | 71.869% |
| JETEMA, Co., Ltd. | 84.27 Billion KRW | 104.637% |
| OliX Pharmaceuticals,Inc | 27.37 Billion KRW | 114.275% |
| Genomictree Inc. | -43.43 Billion KRW | 91.003% |
| MedPacto, Inc. | -64 Billion KRW | 93.894% |
| D&D Pharmatech | -7.5 Billion KRW | 47.95% |
| EASY BIO,Inc. | 53.21 Billion KRW | 107.344% |
| GI Innovation, Inc. | -4.82 Billion KRW | 18.968% |